7-OH Restrictions Kick In as Poison Control Calls Surge 1,200%

Federal regulations targeting 7-OH, a concentrated form of kratom, are set to take effect as early as Friday, Nov. 13, 2026. The rules specifically restrict products containing higher concentrations of 7-OH and mitragynine pseudoindoxyl, or MGPI. This move impacts a market where estimates suggest between 5 million and 15 million Americans have used kratom in their lifetime.

The new restrictions follow a federal lawsuit filed on Aug. 26 by the American Kratom Association. The group challenged an earlier DEA rule that placed three semi-synthetic opioids, including MGPI, under the same strict controls as heroin and LSD. Advocates argued that rule would criminalize natural kratom products containing trace amounts of MGPI.

In response, the Department of Health and Human Services issued a recommendation on Oct. 9. The DEA subsequently adjusted its approach to focus only on products with elevated levels of 7-OH and MGPI. Officials stated that traditional botanical kratom remains legal and is not the primary target of the new enforcement actions.

Data from 53 U.S. poison control centers reveals a sharp rise in interest and adverse events. Reports of calls related to kratom increased by approximately 1,200% between 2015 and 2025. The dataset, published in a report co-authored by Chris Holstege, a professor of emergency medicine at the University of Virginia, includes 233 deaths associated with kratom during that decade.

Of those deaths, 79% involved the use of multiple substances. The most severe outcomes occurred in patients who combined kratom or 7-OH with opioids, stimulants, or benzodiazepines. However, the report notes that 62% of the calls involved individuals using kratom without other drugs.

Users describe the effects of 7-OH as potent and fast-acting. Tyler, a 38-year-old who used the substance to maintain recovery from an earlier opioid addiction, said the tablets provided a euphoric feeling similar to opioids. He began taking 300 to 400 milligrams daily, a dose roughly ten times higher than that of Angela Wilson, a 44-year-old woman from Delaware who takes 32 to 40 milligrams for chronic pain.

Wilson, who lacks health insurance, described the substance as life-changing for managing endometriosis and depression. She warned that losing access to 7-OH under the new rules would be devastating for her family. Conversely, Tyler experienced debilitating withdrawal symptoms when he tried to stop, describing the process as feeling like the worst flu multiplied by three.

Brian, a 41-year-old former user, spent approximately $150 a day on 1,200 milligrams of 7-OH before quitting in April 2026. He reported that withdrawal from 7-OH was more severe than his previous opioid withdrawal, causing anxiety and gastrointestinal issues. He noted that the substance was easily accessible at gas stations and smoke shops.

Researchers at the National Institute on Drug Abuse state that early studies suggest kratom compounds warrant further study as experimental treatments for substance use disorders. David Epstein, a senior investigator at NIDA, noted that some users become dependent on 7-OH within days, requiring frequent doses to avoid withdrawal symptoms.

The market has expanded rapidly in recent years, with 7-OH products appearing in tablets, gummies, tonics, and chocolate. These items are sold in smoke shops, liquor stores, and gas stations. The new federal restrictions aim to standardize the concentration levels of these semi-synthetic opioids while leaving lower-dose botanical kratom available to consumers.